Study of new drug for chronic hepatitis D
Part of Digestive system, Infections clinical trials.
This study tests a new medicine called Hepalatide for people with chronic hepatitis D, a serious liver infection. It aims to see if the drug can reduce the virus and improve liver health. You may be eligible if you have both hepatitis B and D and are on stable hepatitis B treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had chronic hepatitis B for at least 6 months and are on a stable hepatitis B medication for the last 3 months
- You have tested positive for hepatitis D and have had the virus detected in your blood at least twice, with the last test still showing virus
- Your liver enzyme (ALT) is higher than normal but not extremely high
- You are willing to use effective birth control and not plan pregnancy for 2 years
- You have not been in another clinical trial in the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests whether a new monoclonal antibody (a lab-made protein that fights viruses) is safe and effective in people with chronic hepatitis D infection. Hepatitis D only occurs in people who also have hepatitis B, and this new treatment may help control the virus.
This study follows adults who have ongoing hepatitis D infection along with hepatitis B. It aims to better understand this mixed infection and how these patients do over time.
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
This study tests a new medicine called ZM-H1505R for people with chronic hepatitis B who are already taking standard antiviral therapy. It aims to see if the new drug can help control the infection better.
This trial tests a new drug, GS-4321, for people with chronic hepatitis delta, a serious liver infection. It aims to see if the drug is safe and effective, and compares results in healthy volunteers and those with the virus.
This trial is testing treatments for people with chronic hepatitis D, a serious liver infection. If you have antibodies to the hepatitis D virus (HDV), you may be able to join and help find better ways to manage this condition.
Hear when a new Hepatitis D, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.